logo-loader
viewOrgenesis

Orgenesis teams up with European firm Educell on T-cell research projects

The two companies will utilize the Orgenesis Cell and Gene Therapy Biotech Platform, which includes the company’s POCare network

Cancer cell
The first collaboration will focus on the development of CAR-T and whole-cell-based vaccine platform for use in cancer immunotherapies

Orgenesis Inc (NASDAQ:ORGS) has reached a collaboration deal to conduct cell-based research projects with European cell therapy company Educell Ltd, the company announced Tuesday. 

The two companies will utilize the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform, which includes the company’s point of care (POCare) network and associated technologies. Orgenesis’ POC Network includes leading hospitals and research institutes around the world, the company said.

The first collaboration will focus on the development of CAR-T and whole-cell-based vaccine platform for use in cancer immunotherapies. The parties also plan to collaborate with local medical centers.

“This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world,” Orgenesis CEO Vered Caplan said in a statement. 

READ: Orgenesis to collaborate with Fortune 500 firm Leidos on potential coronavirus treatment

“We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform,” Caplain added. “We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.”

Educell is currently preparing cell therapy products for the treatment of articular cartilage, vesicoureteral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use at the University Medical Centre Ljubljana and other institutions in Slovenia.

“We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies,” Educell CEO Miomir Knežević said. “This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educell’s ability to ensure safety in the process and help to reduce overall manufacturing costs.”

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Orgenesis

Price: 5.56 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $122.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read